Volume 17, Issue 5, Pages (May 2009)

Slides:



Advertisements
Similar presentations
Volume 18, Issue 3, Pages (March 2010)
Advertisements

Volume 16, Issue 3, Pages (March 2008)
Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states by Thu-Hang Pham, Christopher.
Genome-editing Technologies for Gene and Cell Therapy
Volume 16, Issue 5, Pages (November 2014)
Volume 26, Issue 1, Pages (January 2018)
ChIP-Seq Data Reveal Nucleosome Architecture of Human Promoters
The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clones by Nicolas A. Gillet, Nirav Malani, Anat Melamed,
Volume 17, Issue 11, Pages (November 2009)
Volume 10, Issue 7, Pages (July 2017)
Volume 38, Issue 4, Pages (May 2010)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing  Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.
High-Resolution Profiling of Histone Methylations in the Human Genome
Volume 25, Issue 3, Pages (March 2017)
Volume 11, Issue 2, Pages (August 2012)
Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions
Volume 17, Issue 8, Pages (August 2009)
Volume 12, Issue 6, Pages (December 2005)
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Volume 20, Issue 5, Pages (May 2012)
Volume 146, Issue 6, Pages (September 2011)
Volume 61, Issue 1, Pages (January 2016)
Ying-Ying Yu, Ph. D. , Cui-Xiang Sun, Ph. D. , Yin-Kun Liu, Ph. D
Volume 28, Issue 2, Pages (August 2015)
Volume 44, Issue 1, Pages (October 2011)
Volume 19, Issue 4, Pages (April 2011)
Mapping Global Histone Acetylation Patterns to Gene Expression
Volume 18, Issue 2, Pages (April 2005)
Volume 2, Issue 2, Pages (February 2008)
High-Resolution Profiling of Histone Methylations in the Human Genome
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 1, Pages 9-22 (January 2013)
Molecular Monitoring of Chronic Myelogenous Leukemia
Molecular Therapy - Methods & Clinical Development
Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72 Expansion  Zhengrui Xi, Lorne Zinman, Danielle Moreno, Jennifer Schymick,
Genome-editing Technologies for Gene and Cell Therapy
Volume 67, Issue 6, Pages e6 (September 2017)
Volume 128, Issue 6, Pages (March 2007)
Volume 19, Issue 3, Pages (March 2011)
Volume 10, Issue 7, Pages (February 2015)
Volume 18, Issue 4, Pages (April 2010)
Molecular Convergence of Neurodevelopmental Disorders
Human Promoters Are Intrinsically Directional
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Dynamic Regulation of Nucleosome Positioning in the Human Genome
Volume 24, Issue 6, Pages (June 2016)
Olivier Humbert, Nancy Maizels  Molecular Therapy - Nucleic Acids 
Volume 122, Issue 6, Pages (September 2005)
Interactions between Retroviruses and the Host Cell Genome
Volume 20, Issue 7, Pages (August 2017)
Distinct Pathways for snoRNA and mRNA Termination
A HERV-K provirus in chimpanzees, bonobos and gorillas, but not humans
Gene Density, Transcription, and Insulators Contribute to the Partition of the Drosophila Genome into Physical Domains  Chunhui Hou, Li Li, Zhaohui S.
Volume 7, Issue 2, Pages (August 2010)
Volume 9, Issue 3, Pages (November 2014)
Volume 15, Issue 8, Pages (August 2007)
Volume 110, Issue 4, Pages (August 2002)
Volume 15, Issue 4, Pages (April 2007)
The Impressionistic Landscape of Meiotic Recombination
Molecular Therapy - Nucleic Acids
Volume 32, Issue 5, Pages (May 2010)
Molecular Therapy - Nucleic Acids
ChIP-Seq Data Reveal Nucleosome Architecture of Human Promoters
Volume 41, Issue 2, Pages (January 2011)
Manfred Schmid, Agnieszka Tudek, Torben Heick Jensen  Cell Reports 
Volume 20, Issue 6, Pages (June 2012)
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Integrated analysis of gene expression and copy number alterations.
Presentation transcript:

Volume 17, Issue 5, Pages 844-850 (May 2009) Analysis of Lentiviral Vector Integration in HIV+ Study Subjects Receiving Autologous Infusions of Gene Modified CD4+ T Cells  Gary P Wang, Bruce L Levine, Gwendolyn K Binder, Charles C Berry, Nirav Malani, Gary McGarrity, Pablo Tebas, Carl H June, Frederic D Bushman  Molecular Therapy  Volume 17, Issue 5, Pages 844-850 (May 2009) DOI: 10.1038/mt.2009.16 Copyright © 2009 The American Society of Gene Therapy Terms and Conditions

Figure 1 Diagram of integration site recovery strategy. (a) Use of a GTAG primer for first round amplification, followed by nested PCR for second round amplification. A detailed description of the VRX496 vector can be found in ref. 20. (b) Use of DNA bar coding to index amplification products during the second round PCR. LTR, long-terminal repeat. Molecular Therapy 2009 17, 844-850DOI: (10.1038/mt.2009.16) Copyright © 2009 The American Society of Gene Therapy Terms and Conditions

Figure 2 Analysis of the information content in the local sequence at HIV integration sites. HIV integration sites in each data set were aligned and conserved bases identified. The y-axes indicate bits of information at each base; perfect conservation of a base would score as two bits. (a) Sequences from HIV infection of Jurkat cells.18 (b) Sequences from the VRX496 ex vivo samples. (c) Sequences from the VRX496 samples recovered from patients. The arrow indicates the location of the host virus DNA junction after integration. HIV, human immunodeficiency virus. Molecular Therapy 2009 17, 844-850DOI: (10.1038/mt.2009.16) Copyright © 2009 The American Society of Gene Therapy Terms and Conditions

Figure 3 Comparison of in vivo and ex vivo lentiviral vector integration sites to the integration sites from control infections of Jurkat cells—analysis of proximity to genomic features. (a) Chromosomal distribution of integration sites in the ex vivo sample, the patient-derived sample, and the control infections of Jurkat cells.18 Random integration would correspond to the line at one. Favored integration is indicated by the bars above the line, disfavored by the bars below. Only every other chromosome is numbered. The right-most chromosome is Y. (b) Frequency of integration in RefGenes. (c) Frequency of integration in Giemsa dark and light bands. The Giemsa dark regions (left side) are higher in gene density. (d) Integration frequency in gene rich regions (scored over 8-Mb intervals surrounding integration sites). (e) Integration frequency in regions of differing transcriptional intensity (scored over 8-Mb intervals surrounding integration sites). The transcriptional intensity measure is similar to the gene density measure, but only genes scored as active using Affymetrix microarrays are counted. (f) Integration frequency in regions of differing CpG island density (scored over 8-Mb intervals surrounding integration sites). (g) Frequency of integration near proto-oncogene 5′-ends. Random integration would have bar heights of one on the y-axis. Molecular Therapy 2009 17, 844-850DOI: (10.1038/mt.2009.16) Copyright © 2009 The American Society of Gene Therapy Terms and Conditions

Figure 4 Comparison of in vivo and ex vivo lentiviral vector integration sites to the integration sites from control infections of Jurkat cells—analysis of proximity to sites of histone methylation and bound DNA binding proteins. Values for each data set were compared to matched random controls. The direction and strength of each trend is quantified using the ROC area method described in ref. 14, the key to the left of the figure indicates the scale. Each row in the plot corresponds to a different form of histone post-translational modification or bound protein as scored in the Barski et al. “ChIP-seq ” data.32 Each column corresponds to an integration site data set. Comparisons were carried out over 1, 10, or 100 kb genomic intervals. ROC, receiver operating characteristic. Molecular Therapy 2009 17, 844-850DOI: (10.1038/mt.2009.16) Copyright © 2009 The American Society of Gene Therapy Terms and Conditions

Figure 5 Ex vivo lentiviral vector integration favors the major grooves of DNA bound on nucleosomes. Positions of lentiviral integration sites on nucleosomes were predicted using the nucleosome prediction algorithm developed by Segal et al. (a) The percentage of total ex vivo lentiviral vector integration sites at each base pair (y-axis) is plotted relative to the dyad axis of nucleosome symmetry (position 0; the scale is in base pairs). (b) Fourier transformation of the data from a, showing the ∼10.5 bp periodicity of integration frequency. Molecular Therapy 2009 17, 844-850DOI: (10.1038/mt.2009.16) Copyright © 2009 The American Society of Gene Therapy Terms and Conditions